Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
57 Obsessive Compulsive Disorder Ocd Trials near San Diego, CA
Power is an online platform that helps thousands of Obsessive Compulsive Disorder Ocd patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerLong-Term Safety of Troriluzole for OCD
San Diego, California
This trial is testing the safety and tolerability of troriluzole as an additional treatment for people with OCD. Troriluzole may help balance brain chemicals to reduce OCD symptoms. Troriluzole is related to riluzole, which has been studied for its potential benefits in treating anxiety disorders and OCD.
Stay on current meds
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Acute Suicidality, Self Injurious Behavior, Others
1200 Participants Needed
Troriluzole for Obsessive-Compulsive Disorder
San Diego, California
This trial is testing troriluzole to see if it can help people with OCD who haven't improved with common medications. Troriluzole works by balancing brain chemicals that may be causing OCD symptoms. The goal is to find a more effective treatment for those who need additional help.
Stay on current meds
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Eating Disorders, Others
Must Be Taking:SSRIs, Clomipramine, Venlafaxine
426 Participants Needed
Exposure Therapy for OCD
San Diego, California
Exposure therapy is the most effective treatment available for obsessive compulsive disorder, yet up to 50% of patients do not recover because the mechanisms underlying successful response are poorly understood, leading to significant variability in how clinicians conduct exposure therapy. The main purpose of this study is to determine which target mechanisms are most critical to engage in real-world exposure sessions to produce good treatment outcomes. Adult participants (N = 400) with Obsessive Compulsive Disorder (OCD) receiving exposure therapy from two sites (McLean Hospital, San Diego State University) across the continuum of care (outpatient, partial hospital, residential) will complete baseline clinical and demographic measures as well as weekly symptom reports. The project will measure exposure mechanisms across three levels of analysis (self-report, observer-rated behavior, physiology) during each exposure session. Mechanisms assessed will include a broad range of variables based on both habituation and inhibitory learning models of exposure. Self-report and observer-rated mechanisms will be measured with the Exposure Feedback Form, created and piloted by the study team. Physiological mechanisms will include skin conductance response, heart rate, and heart rate variability measured with a wristwatch. The current study will determine (1) which exposure mechanisms lead to favorable clinical outcomes, and (2) what makes a good exposure for whom. Results of this study have the potential to improve personalized care for the many patients who do not remit following exposure therapy for OCD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Psychosis, Suicidality, Inpatient Need, Others
400 Participants Needed
Cognitive Rehabilitation and Exposure Therapy for Hoarding Disorder
San Diego, California
Hoarding disorder (HD) is a chronic, progressive, and debilitating psychiatric condition that leads to devastating personal and public consequences, particularly for older adults. This confirmatory efficacy trial will advance our knowledge of the mechanisms of action in the treatment of HD as well as reduce symptom severity, disability, and community consequences.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:50+
Key Eligibility Criteria
Disqualifiers:Psychosis, Mania, Neurodegenerative, Substance Use, Others
Must Not Be Taking:Benzodiazepines
150 Participants Needed
Adjunctive Troriluzole for OCD
La Jolla, California
This trial is testing a new medication called troriluzole to see if it helps people with OCD who aren't getting enough relief from their current treatments. Troriluzole is added to their existing medications and works by changing brain chemicals to reduce OCD symptoms. Troriluzole is related to riluzole, which has shown benefits in treating OCD when used alongside existing treatments.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Not Listed
700 Participants Needed
Troriluzole for Obsessive-Compulsive Disorder
Los Alamitos, California
This trial is testing troriluzole as an extra treatment for people with OCD. It aims to see if the medication can help by balancing brain chemicals, making other treatments work better.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Not Listed
700 Participants Needed
Behavioral Task Performance for Psychiatric Symptoms
Los Angeles, California
This study investigates the computational mechanisms associated with psychiatric disease dimensions. The study will characterize the relationship between computational parameter estimates of task performance and psychiatric symptoms and diagnoses with a longitudinal approach over a 12 month interval. Participants will be healthy participants recruited through Prolific an on-line crowdsourcing service, and psychiatric patients and healthy participants recruited via UCLA Psychiatry Clinics and UCLA's STAND Program
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Neurological Disease, Psychotic Disorders, Substance Use, Others
1100 Participants Needed
TMS + Psychotherapy for OCD
Los Angeles, California
This study will test how people with OCD respond to a type of noninvasive brain stimulation, repetitive Transcranial Magnetic Stimulation (rTMS), when it is combined with psychotherapy. Participants will either engage in Exposure and Response Prevention (ERP) Therapy or supportive therapy (ST) while receiving rTMS. Biobehavioral data from wearable devices and smartphones will be collected to better predict treatment responses. Participants will also undergo repeat resting state functional Magnetic Resonance Imaging (rsfMRI) in order to assess neural predictors and mechanisms of treatment response.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Substance Use, Suicidality, Psychosis, Seizures, Others
Must Be Taking:Serotonin Reuptake Inhibitors
48 Participants Needed
Focused Ultrasound for Obsessive-Compulsive Disorder
Santa Monica, California
This trial is testing the safety and effectiveness of using sound waves directed at the brain to treat patients with OCD who may not respond to usual treatments. The sound waves target a specific brain area to change its activity and reduce symptoms.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cancer, Neoplastic Illness, Others
30 Participants Needed
Psilocybin for OCD
Tucson, Arizona
Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with OCD. The investigators propose to study 20 patients with symptomatic OCD who are not taking mind altering medications or street drugs, to participate in a 12 week study. Participants will be assigned (by luck of the draw) to take low or high dose psilocybin in four dosing sessions separated by 3 weeks. Measurements for the severity of OCD, ability to function, perception of quality of life, safety and tolerability will be measured at baseline prior to drug administration, during the dosing periods, and at the end of study. Other measurements will include brain imaging via fMRI and brain tracing via electroencephalogram (EEG). The investigators believe that during medically supervised dosing sessions, both doses of psilocybin will be safe and well tolerated, and will reduce OCD symptoms. Because psilocybin is a potent drug and especially at the higher dose may induce altered states of consciousness, a thoughtfully implemented procedure for participant safety is in place. Information will be obtained to explore the effects of altered states of consciousness in the outcome of treatment and to find the mechanism of benefit.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Psychosis, Cardiovascular Disease, Others
Must Not Be Taking:Antidepressants, Antipsychotics, Sedatives, Opioids
20 Participants Needed
Transcranial Magnetic Stimulation for Mental Illness
Sunnyvale, California
Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cluster B Disorders, PTSD, Others
Must Not Be Taking:Ketamine, Esketamine, ECT
180 Participants Needed
Ketamine for Obsessive-Compulsive Disorder
Stanford, California
This trial aims to understand how ketamine quickly improves symptoms in people with Obsessive-Compulsive Disorder (OCD). Ketamine works by blocking a specific brain receptor, which helps reduce repetitive thoughts and behaviors. Recent research demonstrated that ketamine rapidly reduces OCD symptoms. The study focuses on how this process happens at different levels in the brain.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Psychiatric, Neurological, Pregnancy, Others
Must Not Be Taking:Drug Interactions
120 Participants Needed
Focused Ultrasound Capsulotomy for Obsessive-Compulsive Disorder
Palo Alto, California
The goal of this clinical trial is to determine if ExAblate MR-guided Focused Ultrasound (MRgFUS) bilateral anterior capsulotomy can be used safely and effectively to relieve symptoms of moderate to severe obsessive compulsive disorder (OCD) in individuals who have not benefited from psychotherapy and medications.
The main questions it aims to answer are:
1. Can ExAblate MRgFUS capsulotomy be safely delivered to individuals suffering from treatment-refractory OCD through an intact skull with a risk and side-effect profile that is comparable to other neurosurgical approaches for capsulotomy?
2. Will ExAblate MRgFUS capsulotomy result in improvement in clinical symptoms and quality of life metrics that are similar to those seen with other surgical approaches for capsulotomy?
In the first stage of the study, participants with severe, treatment resistant OCD (n=10) will be recruited in two centers (Harvard and Stanford) and treated with best medical care (BMT) for 6 months. Thereafter, they will receive the ExAblate MRgFUS procedure and then another BMT for 12 months. In the second stage of the study, participants with moderate to severe OCD (n=56) will be recruited in a multi-center study and treated with BMT plus real or sham MRgFUS for 12 months. Thereafter, those who received sham MRgFUS and did not improve will receive real MRgFUS and then treated with BMT for another 12 months.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Age:25 - 64
Key Eligibility Criteria
Disqualifiers:Psychosis, Bipolar, Substance Use, Others
Must Be Taking:SSRIs, SNRIs, TCAs, Others
66 Participants Needed
Dextromethorphan + Fluoxetine for Obsessive-Compulsive Disorder
Stanford, California
This trial is testing if a common cough medicine can help when taken with a low dose of a usual obsessive-compulsive disorder (OCD) medication. It targets patients with OCD and related disorders who often do not get enough help from current treatments. The cough medicine might work with the usual drug to better control troubling thoughts and actions. The usual medication is a well-established treatment for obsessive-compulsive disorder and has been shown to be effective in multiple studies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Bipolar, Psychotic, Substance Use, Others
Must Be Taking:Fluoxetine
60 Participants Needed
Nitrous Oxide for Obsessive-Compulsive Disorder
Stanford, California
This trial uses nitrous oxide gas, commonly known as laughing gas, to see if it can quickly help people with OCD. It targets individuals with OCD because they often struggle with persistent and distressing thoughts and behaviors. The gas might work by altering brain chemicals to improve mood and reduce symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Nursing, Unsafe Conditions, Others
Must Not Be Taking:Drug Interactions
45 Participants Needed
RR-HNK for OCD
Palo Alto, California
The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Allergy To Ketamine, Pregnancy, Others
45 Participants Needed
Ketamine for Obsessive-Compulsive Disorder
Stanford, California
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Pregnancy, Metal In Body, Others
Must Not Be Taking:Psychotropic, Naltrexone, Ketamine
150 Participants Needed
MDMA-Assisted CBT for Obsessive-Compulsive Disorder
Palo Alto, California
The study assesses the safety and preliminary effectiveness of MDMA-assisted cognitive behavioral therapy in participants diagnosed with obsessive-compulsive disorder (OCD).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Underweight, Others
Must Not Be Taking:Psychotropic Medications
40 Participants Needed
Caloric Vestibular Stimulation for OCD
Stanford, California
This trial investigates if using warm or cold water in the ear can help people with obsessive-compulsive disorders better understand their condition by stimulating certain brain areas.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Vertigo, Otological Surgery, Substance Use, Others
16 Participants Needed
Improv + ERP Therapy for OCD
Stanford, California
The goal of this study is to pilot test a novel group therapy intervention for adults with OCD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Active Suicidality, Medical Illness, Others
12 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
rTMS for Obsessive-Compulsive Disorder
Stanford, California
The goal of this clinical trial is to discover brain-based subtypes of Obsessive Compulsive Disorder (OCD) and examine treatment response to two different repetitive transcranial magnetic stimulation (rTMS) targets in the brain: the medial prefrontal cortex (MPFC) and the right prefrontal cortex (rPFC).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Psychotic Symptoms, Bipolar, Substance Use, Others
Must Be Taking:SRI Medication
360 Participants Needed
Accelerated Theta-Burst Stimulation for Obsessive-Compulsive Disorder
Stanford, California
This study evaluates an accelerated schedule of theta-burst stimulation using a Transcranial Magnetic Stimulation (TMS) device for treatment-resistant Obsessive Compulsive Disorder (OCD). In a randomized fashion, half the participants will receive accelerated theta-burst stimulation at the dorsomedial prefrontal cortex (DMPFC), while half will receive accelerated theta-burst stimulation at the right orbitofrontal (rOFC) site.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Psychosis, Bipolar, Severe Depression, Others
Must Be Taking:Serotonin Reuptake Inhibitors
180 Participants Needed
Aftercare Treatment for Obsessive-Compulsive Disorder
Stanford, California
The purpose of this study is to provide participants diagnosed with obsessive compulsive disorder (OCD) and completed one of the active study protocols at the Rodriguez Lab, with open/aftercare treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Children, Active Suicidality
200 Participants Needed
Deep Brain Stimulation for Obsessive-Compulsive Disorder
Stanford, California
This trial tests a device that sends electrical signals to the brain in patients with severe OCD who don't respond to usual treatments. The electrical pulses aim to help control OCD symptoms. This experimental treatment has shown promising results for severe OCD.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 75
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Eating Disorders, Others
Must Be Taking:SSRIs, Antipsychotics, Clomipramine
10 Participants Needed
Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder
San Francisco, California
This is a pilot study to examine the tolerability, safety and early efficacy of two forms of transcranial magnetic stimulation (TMS) for treating adolescents with Obsessive Compulsive Disorder (OCD) who have experienced limited improvements with usual treatments for OCD in adolescents.
The project's primary goal is to examine whether adolescents can complete 3 consecutive weeks of TMS administered 5 days per week, and to describe the type of and how common individual side effects with TMS occur in adolescents with OCD.
Participants will:
* visit the clinic every weekday for 3 weeks (15 days) to receive TMS treatments
* have a brain MRI scan before TMS treatments begins and after finishing all TMS
* complete questionnaires and report changes in behavior and physical symptoms
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:13 - 17
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Seizure, Others
Must Not Be Taking:Antidepressants, Antipsychotics
30 Participants Needed
Brain Stimulation for Obsessive-Compulsive Disorder
San Francisco, California
The purpose of this study is to identify abnormal brain signals associated with Obsessive Compulsive Disorder (OCD) and psychiatric symptoms and to investigate novel therapeutic stimulation sites. While treating OCD with standard deep brain stimulation (DBS) therapy, the investigators will also monitor the activity of the anterior cingulate and prefrontal cortex, a region known be involved with OCD, decision making, and emotion regulation, and the investigators will identify abnormal activity corresponding to the severity of a patient's OCD. The investigators will also investigate whether it is possible for stimulation delivered to these parts of the brain can improve OCD symptoms. These investigations have the potential to aid in the development of improved forms of DBS that can better target abnormal OCD brain signatures in the future.
The investigators will implant a cortical electrode in addition to the ALIC DBS electrode and connect these to an implantable pulse generator that care store field potential data (Medtronic Percept). The decision whether the lead is placed in the prefrontal or cingulate cortex bilaterally will be based upon considerations of the surgical risks for a particular patient based upon their anatomy and the required surgical approach.
At multiple time points post-implantation up to 2 years, in our clinic or patient's homes, cortical and subcortical signals will be recorded. Data will be collected while patient are resting or engaged in symptom provocation tasks, emotional/cognitive tasks while cortical stimulation is on and off. In addition to brain signal recordings, symptoms will be assessed using validated questionnaires and tasks to allow identification of neurophysiological correlates of OCD symptoms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 75
Key Eligibility Criteria
Disqualifiers:Hoarding, Severe Psychiatric Disorder, Pregnancy, Others
Must Be Taking:SSRIs, Clomipramine, Antipsychotics
15 Participants Needed
Deep Brain Stimulation for Obsessive-Compulsive Disorder
San Francisco, California
This is a double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of 4-lead DBS surgery with bilateral IPGs and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 75
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Substance Abuse, Others
Must Be Taking:SSRIs, Antipsychotics, Clomipramine
10 Participants Needed
TMS for Anorexia
San Francisco, California
This trial uses a type of brain stimulation called theta burst rTMS to treat adults with Anorexia Nervosa. The treatment targets a specific brain area involved in obsessive and compulsive behaviors. The goal is to reduce these symptoms and improve patients' eating habits. Theta burst stimulation (TBS) is a newer and more effective form of repetitive transcranial magnetic stimulation (rTMS) that has shown promise in treating neuropsychiatric disorders.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:16 - 75
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Seizure Disorder, Others
Must Be Taking:Psychotropic Medications
20 Participants Needed
Exposure and Response Prevention for Obsessive-Compulsive Disorder
White City, Oregon
This trial will test a therapy called ERP, which helps people face their fears and stop doing habits that make them feel temporarily better but keep the problem going. It will focus on Veterans with OCD, including those who also have PTSD. The goal is to see if this therapy improves their daily functioning and quality of life.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Psychosis, Mania, Others
160 Participants Needed
Exposure-Based Therapy for Anxiety Disorders
Austin, Texas
Anxiety-, obsessive-compulsive and trauma- and stressor-related disorders reflect a significant public health problem. This study is designed to evaluate the predictive power of a novel biomarker based on a CO2 challenge, thus addressing the central question "can this easy-to-administer assay aid clinicians in deciding whether or not to initiate exposure-based therapy?"
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Bipolar, Psychotic, Substance Use, Others
600 Participants Needed
Know someone looking for new options?
Spread the word